Improved diagnosis, therapy and outcomes for patients with CUP

Slides:

Advertisements

Similar presentations

Cancer of Unknown Primary

Advertisements

Cancer of Unknown Primary Dr Chris Jones Consultant Medical Oncologist North of England Cancer Network Annual Conference 20 September 2013.

A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.

Rarer Sarcoma Subtypes Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Boston, MA.

Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.

Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.

Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.

PET after Chemotherapy in Rhabdomyosarcoma Connective Tissue Oncology Society November 19, 2005 Michelle L. Klem, Leonard H. Wexler, Ravinder Grewal, Heiko.

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.

Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.

High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: results from DBCG77B randomized trial 1 San Antonio.

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin Hoadley, KA et al. Cell 158(4):

Provisional MUO Audit Tania Tillett Medical Oncologist RUH.

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.

XXV^ Riunione Nazionale MITO Innovation in gynecologic cancer: optimal therapy, quality of life, precision medicine. Naples, June Targeting.

R2 김재민 / Prof. 정재헌 Journal conference 1.

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Brain imaging prior to lung cancer resection

Correlation of tumor mutation burden and chemotherapy outcomes

Immunoscore Prognostic in Colon Cancer

Wijendra Senarathne1, Peggy Gates1, Semir Vranic2, Zoran Gatalica1

Brain imaging prior to lung cancer resection

Presented By Michael Lee at 2016 ASCO Annual Meeting

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

MCW Regional Cancer Therapy Program

CUP SSG May 2016 Dr Matt sephton

THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.

Intervista a Federico Cappuzzo

Patient Case 1 Patient Case 1: PET/CT Scan.

Information for participating Sites

Knowledge l Action l Impact

Kantarjian H et al. Cancer 2009;[Epub ahead of print].

CD25 expression is associated with unfavorable clinical outcome.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Monitoring EGFR mutation status in Non-small cell lung cancer (NSCLC) patients using circulating Tumour DNA (ctDNA). Matthew Smith Molecular Pathology.

Dr T P E Wells 13 July 2018 Breast SSG Bath

Figure 4 Example of a patients with CUP

Figure 2 Examples of histopathological validation

Database and Projects Amit Patel.

Fig. 1. scRNA-seq applications in cancer medicine.

What’s new in stage III lung cancer?

Nat. Rev. Urol. doi: /nrurol

MX39795 Study Design Category 1 R 3:1 Category 2 Inclusion criteria

Role for XRT in treatment of early stage Follicular lymphoma?

Introduction Results Materials and Methods Conclusions References 1

Figure 3 Determination of the primary site

CUP is a clinico-pathological syndrome of many specific cancer

Solving Unknown Primary cancER (SUPER)

Empiric versus Site-Directed Chemotherapy in Cancer of Unknown Primary

Pairwise comparison for lung cancer or unspecified cancer diagnosis for most frequent biopsy sites (lung or lymph node). Pairwise comparison for lung cancer.

Esteller, New England Journal of Medicine, 2008

Talk outline Brief history of gene-expression profiling for cancer type classification Current commercially available tests - development and performance.

Next-Generation Sequencing and ctDNA

Kantarjian HM et al. Blood 2008;112:Abstract 635.

Overall Survival and Progression-free Survival

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

Opening remarks Welcome to CUP 2019: Cancer of Unknown Primary in the Era of Precision Medicine Focus: Contemporary Clinical Management and International.

MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Possible outcomes of therapeutic treatments using the spiral model.

Defining the eTME genes.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

E2F4 program is predictive of the efficacy of intravesical BCG immunotherapy in NMIBC. A, the survival curves of intravesical therapy-treated and untreated.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Improved diagnosis, therapy and outcomes for patients with CUP F. Anthony Greco 2016

Introduction Primary may only be found at autopsy Series of 884 autopsies on CUP patient; 75% had small (clinically occult) primaries 1980s: favourable subsets identified (15% of CUP pts). Treated like corresponding primary. 1990s: empirical chemo explored. Limited clinical benefit; median OS 9 months 2000s: Improved IHC & molecular cancer-classifier assays

Molecular Cancer-Classifier Assays Benefit is established Only 30% of CUP pts receive an accurate single-cancer type diagnosis on IHC MCCA complement IHC + clinical features = establish tissue-of-origin diagnosis in 90% of pts.

Molecular Cancer-Classifier Assays Moran et al- multicentre retrospective study, 216 CUP pts, EPICUP test: -Single tissue-of-origin predicted for 187/216 (87%) -33/38 (87%) pts who had latent primary identified matched that of MCCA. -31 pts received chemo considered SOC based on MCCA prediction; median OS 13.6 months -61 pts who received empirically selected chemo, not considered SOC based on MCCA; median OS 6 months (p=0.0051)

Molecular Cancer-Classifier Assays Hainsworth et al- multicentre, prospective study, CancerTYPE ID: Single tissue of origin (one of 26 types) predicted for 98% of pts Site-specific therapies selected according MCCA; median OS 13.4 months Historical control group receiving empirical chemo; median OS 9.1 months ‘Responsive’ cancer types on MCCA; median OS 13.4 months ‘Less responsive’ cancer types on MACC; median OS 7.4 months (p=0.04).

Molecular Cancer-Classifier Assays Other small number, mostly retrospective studies, showing OS benefit if MCCA guides site-specific treatment. Paper suggests CUP biopsy samples should be tested with IHC panel and MCCA, if necessary. Patients who have a likely single site identified, should then be treated as for that site. Empirical chemo should be for CUP NOS only.

Thoughts NICE ‘Do not use gene-expression-based profiling to identify primary tumours in patients with provisional CUP.’ If site suggested by MCCA, do we organise onward molecular testing to guide treatment even further? Funding for this? Access to drugs/funding? Immunotherapy? Who treats patients- CUP specialist or site oncologist?